Search results
Showing 1 to 13 of 13 results for selpercatinib
Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)
Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations in people 12 years and older.
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)
Evidence-based recommendations on selpercatinib (Retsevmo) for untreated RET fusion-positive advanced non-small-cell lung cancer in adults.
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)
Evidence-based recommendations on selpercatinib (Retsevmo) for previously treated RET fusion-positive advanced non-small-cell lung cancer in adults.
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]
In development [GID-TA11160] Expected publication date: TBC
In development [GID-TA11047] Expected publication date: TBC
In development [GID-TA11398] Expected publication date: TBC
In development [GID-TA11480] Expected publication date: 19 February 2025
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.
In development [GID-TA11289] Expected publication date: TBC
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
In development [GID-TA11301] Expected publication date: TBC